Rituximab biosimilar is under clinical development by Apotex and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase I drugs for Chronic Lymphocytic Leukemia (CLL) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Rituximab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rituximab biosimilar overview
Rituximab biosimilar is under development for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia and follicular lymphoma. It is administered through intravenous route. The drug candidate acts by targeting the B lymphocyte antigen CD20.
Apotex produces and markets generic pharmaceuticals. The company also offers biosimilars, active pharmaceutical ingredients and consumer products. It carries out the research, development, manufacture, and distribution of non-prescription and private label medicines, fine chemicals, and disposable plastics for medical use. The company has R&D facilities in Montreal, Richmond Hill, Brantford, Windsor, Winnipeg, Toronto, Etobicoke, Mississauga, London, Calgary, and Vancouver. It serves patients, healthcare providers and payers, governments, and other pharmaceutical manufacturers. The company operates through subsidiaries, joint ventures and licensing agreements across the Americas, Europe, the Middle East, Africa, and Asia Pacific. Apotex is headquartered in Toronto, Ontario, Canada.
For a complete picture of Rituximab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.